I'm not sure how this links to GB-A, that is, whether the hospitals can get funding from the Statutory Health Funds without GB-A approval.
But it highlights the scale of the opportunity and relatively rapid uptake.
If 84 hospitals do 5 each a year, that's over 400 implants. At current price it's around 8 million in revenue.
I think the Turkish distributor putting Oncosil in the same category as Lutetium treatment is very positive.
Ann: 84 German hospitals can negotiate fee for Oncosil device, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.025(2.30%) |
Mkt cap ! $20.89M | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.09 | $26.73K | 24.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6807 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6617 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| OSL (ASX) Chart |